Shots:
- GRIN has granted Angelini Pharma exclusive rights to commercialize radiprodil worldwide, while GRIN will retain its rights in the US, Canada, & Mexico as well as lead global development
- As per the deal, GRIN will get $50M upfront & ~$520M in development, regulatory & sales milestones, with net sales-based tiered royalties & payments from future sublicenses outside of EU; certain clinical development activities will be co-funded
- Additionally, GRIN has closed a $140M Series D round with $75M from Blackstone Life Sciences & $65M equity investment from Angelini to fund a P-III trial of radiprodil for GRIN-NDD in Q3’25. A P-Ib/IIa (Astroscape) trial is also assessing radiprodil in TSC & FCD type II pts
Ref: GRIN Therapeutics | Image: GRIN Therapeutics & Angelini Pharma| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
